NASDAQ:INFI Infinity Pharmaceuticals (INFI) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free INFI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.01▼$0.1352-Week Range N/AVolume2.48 million shsAverage Volume2.58 million shsMarket Capitalization$726,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial Media Get Infinity Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Infinity Pharmaceuticals Stock (NASDAQ:INFI)Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.Read More Ad Crypto Swap ProfitsGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here INFI Stock News HeadlinesMarch 16, 2024 | nytimes.comPi Day: How One Irrational Number Made Us ModernMarch 14, 2024 | msn.comBiotech bankruptcies hit a record despite sector’s recoveryMarch 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 13, 2024 | benzinga.comDavid Schnell's Net WorthMarch 11, 2024 | msn.comMemphis Police issue alert after mother and two children abductedJanuary 31, 2024 | finance.yahoo.comStryker Expands Prophecy® Surgical Planning System to Include the New Footprint™, Offering Surgeons a Comprehensive View of the Foot and AnkleDecember 22, 2023 | seekingalpha.comAGNPF Algernon Pharmaceuticals Inc.December 12, 2023 | morningstar.comInfinity Pharmaceuticals Inc INFIQMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.December 1, 2023 | seekingalpha.comINFIQ Infinity Pharmaceuticals, Inc.October 16, 2023 | businesswire.comINFI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities ...October 16, 2023 | barrons.comFINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the FirmOctober 15, 2023 | stockhouse.comInfinity Ongoing Deadline AlertOctober 14, 2023 | bloomberg.comDeadline Alert: Bronstein, Gewirtz & Grossman LLC Announces that Infinity Pharmaceuticals, Inc. (INFI) Investors Have OpportuniOctober 10, 2023 | finance.yahoo.comInfinity Pharmaceuticals, Inc. (INFIQ)October 9, 2023 | barrons.comBronstein, Gewirtz & Grossman LLC Notifies Infinity Pharmaceuticals, Inc. (INFI) Investors of Class Action and to Actively Participate!October 2, 2023 | bizjournals.comGutted Cambridge biotech declares bankruptcy after failed merger, layoffsOctober 1, 2023 | markets.businessinsider.comInfinity Investor Shareholder AlertSeptember 29, 2023 | msn.comInfinity Pharmaceuticals reportedly files for Chapter 11September 22, 2023 | finanznachrichten.deFaron Pharmaceuticals Oy: Faron Pharmaceuticals Announces Board ChangesSeptember 18, 2023 | stockhouse.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 16, 2023 | prnewswire.comINFINITY DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their OptionsSeptember 16, 2023 | markets.businessinsider.comROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFISeptember 15, 2023 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 14, 2023 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 13, 2023 | gurufocus.comDirector Adelene Perkins Sells 410,196 Shares of Infinity Pharmaceuticals Inc (INFI)September 13, 2023 | stockhouse.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSee More Headlines Receive INFI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INFI CUSIP45665G30 CIK1113148 Webwww.infi.com Phone(617) 453-1000Fax617-453-1001Employees30Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,370,000.00 Net Margins-1,593.93% Pretax Margin-1,593.93% Return on EquityN/A Return on Assets-113.02% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$2.59 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / BookN/AMiscellaneous Outstanding Shares90,760,000Free Float81,857,000Market Cap$726,000.00 OptionableOptionable Beta1.63 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Lawrence E. Bloch J.D. (Age 57)M.D., Treasurer Comp: $513.61kMr. Seth A. Tasker J.D. (Age 44)CEO, Sr. VP, Gen. Counsel & Sec. Key CompetitorsAditxtNASDAQ:ADTXDMK PharmaceuticalsNASDAQ:DMKBellerophon TherapeuticsNASDAQ:BLPHChina SXT PharmaceuticalsNASDAQ:SXTC180 Life SciencesNASDAQ:ATNFView All CompetitorsInsidersAdelene Q PerkinsSold 410,196 sharesTotal: $28,713.72 ($0.07/share)View All Insider Transactions INFI Stock Analysis - Frequently Asked Questions How were Infinity Pharmaceuticals' earnings last quarter? Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. The biotechnology company earned $0.43 million during the quarter, compared to analysts' expectations of $0.45 million. During the same quarter last year, the company posted ($0.16) earnings per share. What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO? 10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Infinity Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX). This page (NASDAQ:INFI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy SykesThe 3rd Revolution in WarfareWeiss RatingsFed launches fourth dollar overhaulStansberry ResearchAI to Meet the Same Fate as EVs? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Infinity Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.